FMS Stock Overview
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Fresenius Medical Care AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €21.93 |
| 52 Week High | €27.72 |
| 52 Week Low | €16.37 |
| Beta | 0.90 |
| 1 Month Change | 12.23% |
| 3 Month Change | 6.35% |
| 1 Year Change | -5.15% |
| 3 Year Change | -46.04% |
| 5 Year Change | -42.41% |
| Change since IPO | 107.62% |
Recent News & Updates
Recent updates
Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns
Feb 23Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off
Oct 12Fresenius Medical Care: Other Stocks Still Better, But Upside Exists
Jun 01Fresenius Medical Care Q4 2022 Earnings Preview
Feb 21Fresenius: The Company Is Climbing, And I'm At 'Buy'
Jan 06Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)
Oct 27Fresenius Medical gains after report of activist Elliott stake in Fresenius SE
Oct 19Fresenius cut to Hold at Jefferies citing staffing issues and inflation
Oct 10Fresenius gets award to provide dialysis services to U.S. military veterans
Aug 30Fresenius appoints head of pharma unit as new CEO
Aug 19Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat
Jul 30Fresenius Medical Care accused of Medicare fraud in dialysis
Jul 13Fresenius: The Upside Is Getting Bigger
May 02You Really Want To Know About Fresenius Medical Care
Aug 28Fresenius Medical drops 12% on disappointing 2021 outlook
Feb 02Fresenius Medical Care EPS beats by €0.06, misses on revenue
Oct 29Shareholder Returns
| FMS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.2% | 0.6% | 1.7% |
| 1Y | -5.1% | 5.7% | 26.0% |
Return vs Industry: FMS underperformed the US Healthcare industry which returned 6.7% over the past year.
Return vs Market: FMS underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| FMS volatility | |
|---|---|
| FMS Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FMS has not had significant price volatility in the past 3 months.
Volatility Over Time: FMS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 117,128 | Helen Giza | www.freseniusmedicalcare.com |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
Fresenius Medical Care AG Fundamentals Summary
| FMS fundamental statistics | |
|---|---|
| Market cap | US$12.90b |
| Earnings (TTM) | US$525.19m |
| Revenue (TTM) | US$21.15b |
24.6x
P/E Ratio0.6x
P/S RatioIs FMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FMS income statement (TTM) | |
|---|---|
| Revenue | €19.47b |
| Cost of Revenue | €14.52b |
| Gross Profit | €4.95b |
| Other Expenses | €4.47b |
| Earnings | €483.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | 1.65 |
| Gross Margin | 25.42% |
| Net Profit Margin | 2.48% |
| Debt/Equity Ratio | 52.5% |
How did FMS perform over the long term?
See historical performance and comparison